Veracyte Shares Plunge Following Lowered Full-Year Guidance and Analyst Downgrade
Veracyte (VCYT) shares experienced a significant decline of over 50% on Thursday following the company's Q3 2026 earnings release. Although the San Francisco-based cancer diagnostics firm exceeded analyst expectations for its quarterly results, management lowered its full-year financial outlook, triggering investor concern. In response to the revised guidance, Leerink Partners downgraded the stock. The sharp sell-off reflects market sensitivity to the company's adjusted growth projections despite the initial earnings beat.
Tickers: $VCYT
Topics: analyst downgrade earnings report guidance downgrade stock price drop